Gentile Antonio, Gerli Sandro, Di Renzo Gian Carlo
Family Planning Clinic Terme Vigliatore, A,S,P, 5 Via Nazionale S, Biagio, 154 98050, Messina, Italy.
BMC Clin Pathol. 2012 Sep 25;12:17. doi: 10.1186/1472-6890-12-17.
HPV infection is a worldwide problem strictly linked to the development of cervical cancer. Persistence of the infection is one of the main factors responsible for the invasive progression and women diagnosed with intraepithelial squamous lesions are referred for further assessment and surgical treatments which are prone to complications. Despite this, there are several reports on the spontaneous regression of the infection.This study was carried out to evaluate the effectiveness of a long term polyhexamethylene biguanide (PHMB)-based local treatment in improving the viral clearance, reducing the time exposure to the infection and avoiding the complications associated with the invasive treatments currently available.
100 women diagnosed with HPV infection were randomly assigned to receive six months of treatment with a PHMB-based gynecological solution (Monogin®, Lo.Li. Pharma, Rome - Italy) or to remain untreated for the same period of time.
A greater number of patients, who received the treatment were cleared of the infection at the two time points of the study (three and six months) compared to that of the control group. A significant difference in the regression rate (90% Monogin group vs 70% control group) was observed at the end of the study highlighting the time-dependent ability of PHMB to interact with the infection progression.
The topic treatment with PHMB is a preliminary safe and promising approach for patients with detected HPV infection increasing the chance of clearance and avoiding the use of invasive treatments when not strictly necessary.
ClinicalTrials.gov Identifier NCT01571141.
人乳头瘤病毒（HPV）感染是一个全球性问题，与宫颈癌的发生密切相关。感染持续存在是导致侵袭性进展的主要因素之一，被诊断为上皮内鳞状病变的女性需要进一步评估并接受易于引发并发症的手术治疗。尽管如此，仍有一些关于该感染自发消退的报道。本研究旨在评估一种基于聚六亚甲基双胍（PHMB）的长期局部治疗在提高病毒清除率、减少感染暴露时间以及避免与现有侵袭性治疗相关并发症方面的有效性。
100名被诊断为HPV感染的女性被随机分配，一组接受为期六个月的基于PHMB的妇科溶液（Monogin®，Lo.Li. Pharma，罗马 - 意大利）治疗，另一组在同一时期不接受治疗。
与对照组相比，接受治疗的患者在研究的两个时间点（三个月和六个月）有更多人清除了感染。在研究结束时观察到消退率存在显著差异（Monogin组为90%，对照组为70%），突出了PHMB与感染进展相互作用的时间依赖性能力。
对于检测到HPV感染的患者，PHMB局部治疗是一种初步安全且有前景的方法，增加了清除病毒的机会，并在并非严格必要时避免使用侵袭性治疗。
ClinicalTrials.gov标识符NCT01571141。
